FDA outlines pilot to speed IND submissions for up to 10 drug programs

The Food and Drug Administration has released details of a new pilot program designed to accelerate the Investigational New Drug (IND) filing process for selected candidates.

The agency plans to work with up to ten drug development programs and aims to have the pilot in place by the end of the year, with the goal of shortening the timeline to move compounds into Phase 1 trials.

This effort is part of a broader strategy to boost the United States' competitiveness in pharmaceutical innovation, particularly in comparison with China.